Asset profile
simridatug
Protein / enzyme therapeutic
Evidence outlook
No clinical-stage evidence registered
No clinical trials are registered for this drug yet, so there is nothing to grade.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
4 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 4 same-indication; 3 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Simridatug: this drug | Not yet studied | Protein / enzyme therapeutic | — | ||
| Fruquintinib | Approved | Small molecule | VEGFR1/2/3 | ||
| Botensilimab | Phase 3 | Monoclonal antibody | CTLA-4 | ||
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | ||
| PI3Kalpha Precision Therapy | Not yet studied | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.